» Articles » PMID: 17024120

The Relationship Between the Systemic Inflammatory Response, Tumour Proliferative Activity, T-lymphocytic Infiltration and COX-2 Expression and Survival in Patients with Transitional Cell Carcinoma of the Urinary Bladder

Overview
Journal Br J Cancer
Specialty Oncology
Date 2006 Oct 7
PMID 17024120
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration, and COX-2 expression and survival was examined in patients with transitional cell carcinoma of the urinary bladder (n=103). Sixty-one patients had superficial disease and 42 patients had invasive disease. Cancer-specific survival was shorter in those patients with invasive compared with superficial bladder cancer (P<0.001). On univariate analysis, stratified by stage, increased Ki-67 labelling index (P<0.05), increased COX-2 expression (P<0.05), C-reactive protein (P<0.05) and adjuvant therapy (P<0.01) were associated with poorer cancer-specific survival. On multivariate analysis of these significant factors, stratified by stage, only C-reactive protein (HR 2.89, 95% CI 1.42-5.91, P=0.004) and adjuvant therapy (HR 0.29, 95% CI 0.14-0.62, P=0.001) were independently associated with poorer cancer-specific survival. These results would suggest that tumour-based factors such as grade, COX-2 expression or T-lymphocytic infiltration are subordinate to systemic factors such as C-reactive protein in determining survival in patients with transitional cell carcinoma of the urinary bladder.

Citing Articles

Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.

Ferro M, Tataru O, Musi G, Lucarelli G, Abu Farhan A, Cantiello F Diagnostics (Basel). 2022; 12(3).

PMID: 35328139 PMC: 8947693. DOI: 10.3390/diagnostics12030586.


The Prognostic Value of Body Mass Index in Patients With Urothelial Carcinoma After Surgery: A Systematic Review and Meta-Analysis.

Yang Z, Bai Y, Hu X, Wang X, Han P Dose Response. 2021; 18(4):1559325820979247.

PMID: 33402880 PMC: 7745568. DOI: 10.1177/1559325820979247.


An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.

Ferro M, Vartolomei M, Russo G, Cantiello F, Abu Farhan A, Terracciano D World J Urol. 2018; 37(3):507-514.

PMID: 29992381 DOI: 10.1007/s00345-018-2397-1.


HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.

Barnes T, Amir E Br J Cancer. 2017; 117(4):451-460.

PMID: 28704840 PMC: 5558691. DOI: 10.1038/bjc.2017.220.


Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis.

Tian Y, Ma Z, Chen Z, Li M, Wu Z, Hong M PLoS One. 2016; 11(7):e0158891.

PMID: 27410033 PMC: 4943634. DOI: 10.1371/journal.pone.0158891.


References
1.
Habuchi T, Marberger M, Droller M, Hemstreet 3rd G, Grossman H, Schalken J . Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2006; 66(6 Suppl 1):64-74. DOI: 10.1016/j.urology.2005.08.065. View

2.
Edwards J, Mukherjee R, Munro A, Wells A, Almushatat A, Bartlett J . HER2 and COX2 expression in human prostate cancer. Eur J Cancer. 2003; 40(1):50-5. DOI: 10.1016/j.ejca.2003.08.010. View

3.
Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T . Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg. 2003; 238(2):197-202. PMC: 1422696. DOI: 10.1097/01.sla.0000080822.22415.cb. View

4.
Manoharan M, Soloway M . Optimal management of the T1G3 bladder cancer. Urol Clin North Am. 2005; 32(2):133-45. DOI: 10.1016/j.ucl.2005.02.002. View

5.
Lamb G, McMillan D, Ramsey S, Aitchison M . The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer. 2006; 94(6):781-4. PMC: 3216422. DOI: 10.1038/sj.bjc.6603034. View